Treatment News : Merck’s Non-Nuke MK-1439 Shows Antiviral Activity, Is Safe and Well Tolerated

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 11, 2013

Merck’s Non-Nuke MK-1439 Shows Antiviral Activity, Is Safe and Well Tolerated

CROI 2013Merck’s investigatory non-nucleoside reverse transcriptase inhibitor (NNRTI) MK-1439 proved safe and well tolerated—and it displayed robust antiviral activity in a small early trial, aidsmap reports. Representatives from Merck announced findings from a Phase Ib safety and efficacy trial of the non-nuke at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta. The double-blind, placebo-controlled study of 18 treatment-naive patients with HIV divided them into three even groups: The first took 25 milligrams of MK-1439; the second 200 mg of the drug; and the third a placebo. All participants took one dose per day as a monotherapy for seven days.

Three-quarters of participants experienced limited, transient and generally mild to moderate adverse experiences in the study. On the seventh day of the study, those taking 25 mg of MK-1439 saw a mean drop of 1.37log10 in viral load compared with the placebo group, and those taking 200 mg of the drug saw a 1.26log10 drop. No one in the two groups showed evidence of viral breakthrough.

Meanwhile, a second study of MK-1439 to determine its safety and pharmacokinetics (PK) among HIV-negative subjects determined that the drug is suitable for once-a-day dosing and is generally well tolerated. One out of the 72 males in the study experienced elevated liver enzymes, apparently because of muscle damage from heavy physical activity—a reaction the medication may have aggravated. There were no reports of rashes or significant central nervous system adverse reactions outside of headache.

To read the aidsmap story, click here.

To read the study abstract, click here

Search: Merck, non-nuke, non-nucleoside reverse transcirptase inhibitor, NNRTI, MK-1439, aidsmap, Conference on Retroviruses and Opportunistic Infections, CROI, monotherapy.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    Reginaldb06
    Dallas
    Texas


    sefarady
    New York
    California


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.